Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report)’s stock price shot up 8% during trading on Friday . The company traded as high as $15.76 and last traded at $16.1260. Approximately 188,694 shares traded hands during trading, a decline of 81% from the average session volume of 975,209 shares. The stock had previously closed at $14.93.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on VOR shares. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Weiss Ratings downgraded shares of Vor Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 15th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Wells Fargo & Company started coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $42.25.
Read Our Latest Research Report on Vor Biopharma
Vor Biopharma Stock Up 2.7%
Vor Biopharma (NASDAQ:VOR – Get Free Report) last posted its quarterly earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. Sell-side analysts predict that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.
Insider Transactions at Vor Biopharma
In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 589,257 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $16.59, for a total transaction of $9,775,773.63. Following the completion of the transaction, the director owned 4,555,741 shares in the company, valued at $75,579,743.19. This trade represents a 11.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 3,002,903 shares of company stock valued at $49,412,176 over the last three months. Corporate insiders own 0.27% of the company’s stock.
Institutional Investors Weigh In On Vor Biopharma
Hedge funds have recently made changes to their positions in the company. Bank of America Corp DE increased its holdings in shares of Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after buying an additional 112,496 shares in the last quarter. Irenic Capital Management LP acquired a new stake in shares of Vor Biopharma in the 1st quarter valued at $583,000. Renaissance Technologies LLC acquired a new stake in shares of Vor Biopharma in the 1st quarter valued at $2,298,000. Sei Investments Co. bought a new stake in shares of Vor Biopharma during the first quarter worth $245,000. Finally, Independent Financial Group LLC bought a new stake in Vor Biopharma during the 1st quarter worth about $249,000. Institutional investors and hedge funds own 97.29% of the company’s stock.
About Vor Biopharma
Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.
The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Featured Stories
- Five stocks we like better than Vor Biopharma
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
